Zetagen Therapeutics, Inc. Secures $5.34 Million in Series A Funding to Accelerate Clinical Work

• U.S.-based biopharmaceutical company has discovered and patented a novelmolecular pathway intended to treat metastatic bone lesions
• Series A Funding will be used for scientific infrastructure to prepare for initial human clinical study
• Company’s intellectual property pipeline targets other oncologic treatments for Skeletal-Related Events (SRE’s) and osteologic interventions

February 6, 2020, (Syracuse, New York) - Zetagen Therapeutics, Inc., a private, clinical-stage, biopharmaceutical company dedicated to driving breakthrough innovation in the treatment of metastatic bone cancers and osteologic interventions, today announced the close of $5.34M Series A funding round. The financing will accelerate the growth of the Company’s ongoing clinical programs for ZetaMet™ (Zeta-BC-003), a synthetic, small-molecule, inductive biologic being developed to target and resolve metastatic lesions while inhibiting future tumor growth.

“We are extremely pleased to have reached such an important milestone in Zetagen’s advancement as a biopharmaceutical company, ” said Joe C. Loy, CEO of Zetagen Therapeutics, Inc. “This funding is paramount to accelerating our clinical programs around ZetaMet™ (Zeta-BC-003) by adding the necessary scientific infrastructure that will allow us to prepare for future human clinical trials.”

ZetaMet™ (Zeta-BC-003) is a novel molecular pathway paired with a proprietary, drug-eluting implant technology. The novel therapy is designed to resolve tumor growth, inhibit pain, and regenerate bone. Zetagen exclusively licensed the platform technology from the State University of New York in 2016.